Health Care/Hospital

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...

2024-07-28 21:48 3008

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...

2024-07-26 23:21 5701

MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...

2024-07-26 21:02 5858

ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a$30 million Series A financing, bringing the total raised so f...

2024-07-26 21:00 3149

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Eur...

2024-07-26 20:16 9720

MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports

PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports a...

2024-07-26 19:35 3515

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KRW, driven by the strong sales from the key products. * HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) ...

2024-07-26 19:00 4531

Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project

SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient inthe United States. This clinical trial, known as LOTUS, is an open-label, multicenter, si...

2024-07-26 18:00 3859

Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View

PORT VILA, Vanuatu, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker,  Vantage Markets

2024-07-26 17:05 2409

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

SYDNEY, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 3211

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-07-26 10:16 1790

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-07-26 09:33 2842

2024 Milken Institute Asia Summit Casts Spotlight on Impactful Ideas and Purposeful Action

The 11th annual Summit adds a new focus on health and philanthropy, adding content from its flagship Future of Health Summit and Philanthropic Investors Forum to the program agenda.  SINGAPORE, July 26, 2024 /PRNewswire/ -- Global think tank Milken Institute announced today the return of its ann...

2024-07-26 09:02 7031

Angel Yeast Showcases Innovative Yeast Protein Solutions at Growth Asia 2024

SHANGHAI, July 26, 2024 /PRNewswire/ -- Angel Yeast (SH600298), a global leader in yeast manufacturing, recently introduced its yeast protein and innovative application solutions at the Growth Asia 2024 summit, which was co-hosted by leading industry media NutraIngredi...

2024-07-26 01:20 12542

Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024

- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE PET with centiloid scale feature SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announc...

2024-07-25 21:00 1959

Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences

Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China, July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve thera...

2024-07-25 20:30 1996

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

SUZHOU, China, July 25, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RAG-18, one of the company's lead saRN...

2024-07-25 20:00 1859

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif.  , July 25, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces thatthe investigation...

2024-07-25 17:46 2064

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

SINGAPORE, July 25, 2024 /PRNewswire/ -- ObvioHealth , a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research an...

2024-07-25 16:39 2600

MoU signing between HCSA Community Services and Tzu-Chi Foundation (Singapore) to support Hepatitis C elimination initiative for former drug abusers in Singapore

SINGAPORE, July 25, 2024 /PRNewswire/ -- HCSA Community Services and Tzu-Chi Foundation (Singapore) today signed a Memorandum of Understanding (MoU) to formalise support for Phase 2 of the Educate, Test, Treat! (ETT) initiative, which has been supported by biopharmaceutical company Gilead Science...

2024-07-25 11:30 2111
1 ... 55565758596061 ... 847

Week's Top Stories